Targeted drug delivery using immunoconjugates: Principles and applications

Journal of Immunotherapy

Volumn 34, Issue 9, 2011, Pages 611-628

  Pasquetto, Maria Valentina ^a   Vecchia, Luca ^a   Covini, Daniele ^a   Digilio, Rita ^a   Scotti, Claudia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

antibody fragments; antibody drug conjugates; cancer; immunoconjugates; monoclonal antibodies

Indexed keywords

AGS 16M8F; AMG 386; ANTIBODY CONJUGATE; BAY 794620; BLEOMYCIN; BRENTUXIMAB VEDOTIN; BT 062; CARBONATE DEHYDRATASE IX; DACARBAZINE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; IMGN 388; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; PACLITAXEL; RADIUM; RITUXIMAB; SAR 3419; SAR 566658; SGN 75; THORIUM; TOSITUMOMAB I 131; TRASTUZUMAB EMTANSINE; TUCOTUZUMAB CELMOLEUKIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; BONE METASTASIS; BREAST CANCER; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STRUCTURE; FATIGUE; FEVER; GLYCOSYLATION; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; LYMPHOMATOID PAPULOSIS; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NAUSEA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SOLID TUMOR; THERAPY EFFECT; TUMOR; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LIPOSOMES; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; PROTEIN ENGINEERING; PROTEIN STABILITY;

EID: 80055002179     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318234ecf5     Document Type: Review

References (179)

1. Bale WF, Spar IL, Goodland RL. Experimental radiation therapy of tumors with I-131-carrying antibodies to fibrin. Cancer Res. 1960;20:1488-1494.
2. Lindford JH, Froese G, Berczi I, et al. An alkylating agentglobulin conjugate with both alkylating and antibody activity. J Natl Cancer Inst. 1974;52:1665-1667.
3. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256: 495-497.
4. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-357.
5. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3:76-99.
6. ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma [ImmunoGen, Inc.Web site] 2011. Available at: http://http://phx. corporate-ir.net/phoenix.zhtml?c=97573&p=irol- newsArticle& ID=1609366&highlight=. Accessed September 26, 2011.
7. ImmunoGen. ImmunoGen, Inc. Announces First Data for its Novel Therapeutic for Ovarian Cancer and Other Carcinomas (ImmunoGen, Inc. Web site) 2011. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-news Article&ID=1545497&highlight. Accessed July 20, 2011.
8. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122-135.
9. Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther. 2010;10: 1251-1258.
10. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy. 2011;3: 475-485.
11. Sapra P, Hooper AT, O'Donnell CJ, et al. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs. 2011;20:1131-1149.
12. Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs. 2011;20:297-304.
13. Burris HA 3rd, Tibbitts J, Holden SN, et al. Trastuzumab Emtansine (T-DM1): a novel agent for targeting HER2(+) breast cancer. Clin Breast Cancer. 2011. [Epub ahead of print].
14. Beck A, Senter PD, Chari RJ. World Antibody Drug Conjugate Summit Europe: February 21 to 23, 2011. Frankfurt, Germany: MAbs; 2011:3.
15. Deutsch YE, Tadmor T, Podack ER, et al. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011;52:1641-1654.
16. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812-1821.
17. Brentuximab vedotin. Drugs R D 2011;11:85-95.
18. Naumovski L, Junutula JR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010;12:248-257.
19. Burris HA. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther. 2011;11:807-819.
20. Niculescu-Duvaz I. Trastuzumab emtansine, an antibodydrug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther. 2010;12:350-360.
21. ImmunoGen. ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCO [ImmunoGen, Inc. Web site]. 2010. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID= 1435268 &highlight=. Accessed July 20, 2011.
22. Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004;27:232-239. (Pubitemid 39118088)
23. Coiffier B, Ribrag V, Dupuis J, et al, Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL). Asco Annual Meeting. June 2011. Abstract 8017.
24. Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010;16:3044-3056.
25. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009;27:3557-3565.
26. Amgen. Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer [Amgen Web site]. 2010. Available at: http://www.ext. amgen.com/media/media-pr-detail.jsp?year=2010&release ID=1480835. Accessed July 20, 2011.
27. ImmunoGen. ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for Lorvotuzumab Mertansine at ESMO Annual Meeting [ImmunoGen, Inc. Web site]. 2010. Available at: http://phx.corporate-ir.net/phoenix.z html?c=97573&p=irol-newsArticle&ID=1480912&high light=. Accessed July 20, 2011.
28. ImmunoGen. Lorvotuzumab mertansine [ImmunoGen, Inc. Web site]. 2011. Available at: http://www.immunogen.com/wt/page/IMGN901b. Accessed July 20, 2011.
29. Teng LS, Jin KT, He KF, et al. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73:449-456.
30. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085-2093.
31. Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101:1840-1845.
32. Han EJ, Lee SE, Kim SH, et al. Clinical outcomes of postremission therapy using (90)yttrium ibritumomab tiuxetan [Zevalin(R)] for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol. 2011;90:1075-1082.
33. Vitolo U, Barosi G, Fanti S, et al. Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice: a project of the Italian society of hematology. Am J Hematol. 2010;85:147-155.
34. Jacobs SA. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics. 2007;1:215-227.
35. Zhou Y, Zhang L, Romaguera J, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008;83:144-149. (Pubitemid 351147782)
36. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28: 3709-3716.
37. Bodet-Milin C, Kraeber-Bodere F, Dupas B, et al. Evaluation of response to fractionated radioimmunotherapy with 90Yepratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica. 2008;93:390-397. (Pubitemid 351398640)
38. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dosefractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11:5215-5222. (Pubitemid 41003709)
39. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
40. Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J Gastroenterol. 2010;16:5543-5554.
41. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol. 2007;14:632-638. (Pubitemid 47494079)
42. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117:45-52.
43. Chong G, Lee FT, Hopkins W, et al. Phase I trial of 131IhuA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818-4826. (Pubitemid 41568168)
44. Murray JL, Macey DJ, Kasi LP, et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer. 1994;73:1057-1066. (Pubitemid 24046670)
45. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23:6540-6548. (Pubitemid 46190246)
46. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004; 45:1412-1421. (Pubitemid 47618543)
47. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310. (Pubitemid 46464522)
48. Rice SL, Roney CA, Daumar P, et al. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41:265-282.
49. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-1721. (Pubitemid 37254913)
50. Nakajima T, Mitsunaga M, Bander NH, et al. Targeted, activatable, in vivo fluorescence imaging of Prostate-specific Membrane Antigen (PSMA)-positive tumors using the quenched humanized J591 antibody-ICG conjugate. Bioconjug Chem. 2011;22:1700-1705.
51. Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 2009;50(Suppl 1):32-37.
52. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636. (Pubitemid 30220540)
53. Kreitman RJ, Arons E, Stetler-Stevenson M, et al. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):82-86.
54. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005; 23:6719-6729. (Pubitemid 46190267)
55. Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15:5274-5279.
56. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13:5144-5149. (Pubitemid 47502082)
57. Hausner PF, Karp JE, Edelma NL, et al. Phase I study of LMB-9 (B3(dsFv)PE38), a recombinant disulfide stabilized anti-Lewis Y immunotoxin administered by continuous infusion. Proc Am Soc Clin Oncol. 2003:abstr 736.
58. Hassan R, Williams-Gould J, Watson T, et al. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res. 2004;10:16-18. (Pubitemid 38114156)
59. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005;106: 454-457. (Pubitemid 40981237)
60. Kuzel TM, Li S, Eklund J, et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma. 2007; 48:2397-2402. (Pubitemid 350253471)
61. Gerena-Lewis M, Crawford J, Bonomi P, et al. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009;32:269-273.
62. Prince HM, Duvic M, Martin A, et al. Phase III placebocontrolled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:1870-1877.
63. Natarajan N, Telang S, Miller D, et al. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs. 2011;71:1233-1250.
64. Woo JH, Lee YJ, Neville DM, et al. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials. Methods Mol Biol. 2010;651:157-175.
65. Borghaei H, Alpaugh K, Hedlund G, et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced nonsmall-cell lung cancer. J Clin Oncol. 2009;27:4116-4123.
66. Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expert Opin Biol Ther. 2010;10:273-279.
67. Castelletti D, Fracasso G, Righetti S, et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol. 2004; 136:365-372. (Pubitemid 38543458)
68. Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003;14:729-736. (Pubitemid 36621773)
69. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 2000;14: 129-135. (Pubitemid 30068384)
70. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgGRFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85:3457-3465.
71. TargaTherapeutics. Human Clinical Trials Results with HuM195/rGel [TargaTherapeutics Web site]. Available at: http://www.targatherapeutics.com/ payloads.html. Accessed July 21, 2011.
72. Food and Drug Administration. FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market [FDA Web site]. 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm, Accessed July 21, 2011.
73. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529-537.
74. Food and Drug Administration. Brentuximab Vedotin [FDA Web site]. 2011. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm268969.htm, Accessed September 26, 2011.
75. Krop I, Lo Russo P, Miller KD, et al, A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer who were Previously Treated with an Anthracycline, a Taxane, Capecitabine, Lapatinib, and Trastuzumab. 32nd Annual San Antonio Breast Cancer Symposium. 2009. Abstract 710.
76. Stein R, Smith MR, Chen S, et al. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 2009;15:2808-2817.
77. Ricart AD. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther. 2011;89:513-523.
78. Stohrer M, Boucher Y, Stangassinger M, et al. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000;60: 4251-4255. (Pubitemid 30636613)
79. Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol. 1992;14:457-463.
80. Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys. 1982;215:1-11. (Pubitemid 13194163)
81. Alley SC, Zhang X, Okeley NM, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009;330:932-938.
82. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun. 2003;24:951-957. (Pubitemid 39625408)
83. Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005; 24:539-567. (Pubitemid 43097000)
84. Postema EJ, Boerman OC, Oyen WJ, et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med. 2001;28:1725-1735. (Pubitemid 33036117)
85. Koppe MJ, Bleichrodt RP, Oyen WJ, et al. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92: 264-276. (Pubitemid 40445588)
86. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv. 2011;8:26-44.
87. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221-237. (Pubitemid 46706511)
88. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res. 2004;10:13-15. (Pubitemid 38114155)
89. Hall PD, Virella G, Willoughby T, et al. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol. 2001;100:191-197.
90. Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin a chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv. 1987;4:245-253.
91. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009;100:1359-1365.
92. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep. 2010;5:140-147.
93. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999;11:541-547. (Pubitemid 29462130)
94. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
95. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
96. Kapoor P, Greipp PT, Morice WG, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141:135-148. (Pubitemid 351406208)
97. Crocker PR, Clark EA, Filbin M, et al. Siglecs: a family of sialic-acid binding lectins. Glycobiology. 1998;8:v.
98. Hatta Y, Tsuchiya N, Matsushita M, et al. Identification of the gene variations in human CD22. Immunogenetics. 1999;49:280-286. (Pubitemid 29119037)
99. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3-S8. (Pubitemid 32938123)
100. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31: 637-643. (Pubitemid 29248872)
101. Maresch J, Schoppmann SF, Thallinger CM, et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol. 2011. [Epub ahead of print].
102. Zhang Q, Feng W, Zhou H, et al. Advances in preclinical small molecules for the treatment of NSCLC. Expert Opin Ther Pat. 2009;19:731-751.
103. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1999;96:2110-2115. (Pubitemid 29117876)
104. Kandel ES, Skeen J, Majewski N, et al. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002;22:7831-7841. (Pubitemid 35217294)
105. Somanath PR, Razorenova OV, Chen J, et al. Akt1 in endothelial cell and angiogenesis. Cell Cycle. 2006;5:512-518. (Pubitemid 43340529)
106. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534-2539.
107. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275:547-550. (Pubitemid 27051913)
108. Ran S, Gao B, Duffy S, et al. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998;58:4646-4653. (Pubitemid 28480630)
109. Matsuno F, Haruta Y, Kondo M, et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999;5:371-382. (Pubitemid 29085191)
110. Olson TA, Mohanraj D, Roy S, et al. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer. 1997;73:865-870. (Pubitemid 127483042)
111. Arora N, Masood R, Zheng T, et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 1999;59:183-188. (Pubitemid 29062976)
112. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380. (Pubitemid 28063372)
113. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-2407. (Pubitemid 34734217)
114. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release. 1998;53:49-67. (Pubitemid 28218689)
115. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62. (Pubitemid 37361624)
116. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009;198: 157-174.
117. Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2:77-83.
118. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009;27:331-337.
119. Sutherland S. Peptibodies: the new cool technology. Drug Discov Today. 2004;9:683. (Pubitemid 39070275)
120. Hudson PJ, Souriau C. Engineered antibodies. Nat Med. 2003;9:129-134. (Pubitemid 36098274)
121. Rathanaswami P, Roalstad S, Roskos L, et al. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun. 2005;334:1004-1013. (Pubitemid 41074676)
122. Erickson HK, Park PU, Widdison WC, et al. Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426-4433.
123. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5-13.
124. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113-135. (Pubitemid 30089760)
125. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925-932.
126. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibodydrug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69: 2358-2364.
127. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res. 2007;13: 5586s-5591s. (Pubitemid 47510391)
128. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev. 2008;60:1347-1370.
129. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins. 2011;3:848-883.
130. Kovtun YV, Audette CA, Mayo MF, et al. Antibodymaytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70:2528-2537.
131. Amador ML, Jimeno J, Paz-Ares L, et al. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol. 2003;14:1607-1615. (Pubitemid 37460970)
132. Schwartsmann G, Da Rocha AB, Mattei J, et al. Marinederived anticancer agents in clinical trials. Expert Opin Investig Drugs. 2003;12:1367-1383. (Pubitemid 36957792)
133. Banerjee S, Wang Z, Mohammad M, et al. Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod. 2008;71:492-496. (Pubitemid 351549382)
134. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784. (Pubitemid 36791396)
135. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10:7842-7851. (Pubitemid 39587522)
136. Lee MD, Manning JK, Williams DR, et al. Calicheamicins, a novel family of antitumor antibiotics. 3: isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo). 1989;42:1070-1087.
137. Zein N, Sinha AM, McGahren WJ, et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240: 1198-1201.
138. Williams DP, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem. 1990;265:11885-11889.
139. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 2000;27: 62-73. (Pubitemid 32164597)
140. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269. (Pubitemid 34831524)
141. Larson SM. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst. 1991;83:1602-1604.
142. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11:375-380. (Pubitemid 29410880)
143. Akhtar NH, Pail O, Saran A, et al. Prostate-specific membrane antigen-based therapeutics. Advances in Urology. 2012;2012:973820.
144. Tietze LF, Krewer B. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem Biol Drug Des. 2009;74:205-211.
145. Chen KC, Wu SY, Leu YL, et al. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. Bioconjug Chem. 2011; 22:938-948.
146. Afshar S, Olafsen T, Wu AM, et al. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT. J Exp Clin Cancer Res. 2009;28:147.
147. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19: 311-330. (Pubitemid 40316520)
148. Lee PY, Wong KK. Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv. 2011;8:245-253.
149. Singhal S, Nie S, Wang MD. Nanotechnology applications in surgical oncology. Annu Rev Med. 2010;61:359-373.
150. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976. (Pubitemid 39014473)
151. McElroy M, Kaushal S, Luiken GA, et al. Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg. 2008;32:1057-1066.
152. Kaushal S, McElroy MK, Luiken GA, et al. Fluorophoreconjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg. 2008;12:1938-1950.
153. Cardo-Vila M, Giordano RJ, Sidman RL, et al. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci USA. 2010;107:5118-5123.
154. Adriaenssens E, Vanhecke E, Saule P, et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 2008;68:346-351. (Pubitemid 351380059)
155. Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11:1000-1017.
156. Aggarwal S, Yadav S, Gupta S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol. 2011;7:137-138.
157. Bangham AD. Physical structure and behavior of lipids and lipid enzymes. Adv Lipid Res. 1963;1:65-104.
158. Gregoriadis G, Ryman BE. Lysosomal localization of-fructofuranosidase- containing liposomes injected into rats. Biochem J. 1972;129:123-133.
159. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997;54(Suppl 4):8-14.
160. Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev. 1999;40:103-127. (Pubitemid 29486607)
161. Sharma S, Sharma N, Kumar S, et al. Liposomes: a review. J Pharm Res. 2009;2:1163-1167.
162. Niu J, Dorahy DJ, Gu X, et al. Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the beta6 integrin subunit. Int J Cancer. 2002;99:529-537. (Pubitemid 34461605)
163. Maruyama K, Ishida O, Takizawa T, et al. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev. 1999;40:89-102. (Pubitemid 29486606)
164. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987;3:123-193. (Pubitemid 17219201)
165. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst. 1992;9:39-90.
166. Greenfield RS, Kaneko T, Daues A, et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acidsensitive hydrazone linker. Cancer Res. 1990;50:6600-6607. (Pubitemid 20348786)
167. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261:212-215. (Pubitemid 23265398)
168. King HD, Staab AJ, Pham-Kaplita K, et al. BR96 conjugates of highly potent anthracyclines. Bioorg Med Chem Lett. 2003;13:2119-2122. (Pubitemid 36694287)
169. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113:171-199.
170. Bendas G, Krause A, Bakowsky U, et al. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm. 1999;181:79-93. (Pubitemid 29199890)
171. Maruyama K, Takahashi N, Tagawa T, et al. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 1997;413:177-180. (Pubitemid 27348659)
172. Vegarud G, Christensen TB. The resistance of glycoproteins to proteolytic inactivation. Acta Chem Scand B. 1975;29:887-888.
173. Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs. 2010; 24:9-21.
174. Sola RJ, Rodriguez-Martinez JA, Griebenow K. Modulation of protein biophysical properties by chemical glycosylation: biochemical insights and biomedical implications. Cell Mol Life Sci. 2007;64:2133-2152. (Pubitemid 350092414)
175. Abes R, Gelize E, Fridman WH, et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116:926-934.
176. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 1985;54:631-664. (Pubitemid 15073660)
177. Visintin M, Tse E, Axelson H, et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA. 1999;96:11723-11728. (Pubitemid 29502799)
178. Welt S, Mattes MJ, Grando R, et al. Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. Proc Natl Acad Sci USA. 1987;84: 4200-4204. (Pubitemid 17090901)
179. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol. 2007;18:295-304. (Pubitemid 47385180)